VANCOUVER, British Columbia, Aug. 14, 2018 (GLOBE NEWSWIRE) — Kaneh Bosm BioTechnolgy Inc. (CSE: KBB)(FWB: 8K51)(OTC: KNHBF)(“Kaneh Bosm” or the “Company”) is pleased to announce that it has applied for eligibility to The Depository Trust Company (“DTC”) for its shares trading on the OTC market.
DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that manages the electronic clearing and settlement of publicly traded companies in the United States. DTC eligibility will simplify the process of trading and is expected to enhance liquidity of the Company’s common shares on the OTC marketplace, where Kaneh Bosm now trades under the symbol KNHBF. The Company is optimistic that it will be fully DTC-eligible in the next coming week.
Eugene Beukman Chief Executive Officer of Kaneh Bosm states, “The Company’s listing on the OTC marketplace, combined with DTC eligibility will provide a more efficient process for Amercian investors to participate as shareholders during this exciting growth period. Kaneh Bosm’s visibility on a U.S.-based marketplace provides us great confidence as we continue to establish our company within the American investment community.”
On behalf of the Board of Directors of Kaneh Bosm Biotechnology Inc.
THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.
This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com
Kaneh Bosm BioTechnology Inc.
810 – 789 West Pender Street
Vancouver BC V6C 1H2